Skip to main content

Use and overuse of proton pump inhibitors

In 2009, an editorial by Putman focused on the dramatic increase in the use of proton pump inhibitors (PPIs) in infants [1]. Considering the increasing evidence that PPIs offer little benefit for most of the symptoms for which they are prescribed, Putman strongly highlighted the need for a serious effort to curtail their empiric use. The editorial was linked to a study by Orenstein et al, which detected no difference in efficacy between lansoprazole and placebo for symptoms attributed to gastroesophageal reflux disease (GERD) in infants [2]. A very recent review on the effects of PPIs on irritability and crying in infants confirmed the conclusion that these drugs do not offer relief from these symptoms for which they are commonly prescribed [3]. After all, it has recently been pointed out that volume rather than acid is often the key promoter of reflux-associated symptoms in infants. Distension-induced increase in gastric wall tension has been associated with high rates of transient lower esophageal sphincter relaxations and is considered one of the main mechanisms contributing to postprandial GER [4]. Despite all these evidences on PPIs uneffectiveness for many of the symptoms for which they are commonly prescribed, the rate of their prescriptions have exponentially increased over the last years. The latest combined NASPGHAN/ESPGHAN guidelines already in 2009 highlighted the need to distinguish physiologic GER events from GERD, limiting for the latter the use of PPIs [5]. However, a 2012 European survey carried out by our study group showed that only 1.8% of pediatricians reported a complete adherence to the guideline recommendations in their clinical practice. The most relevant violation of the guideline recommendations concerned the prescription of unnecessary acid suppressive medications [6] (Figure 1). In order to inquire into the reasons why pediatricians did not follow the guideline recommendations, we performed another trial with the same pediatricians undergoing specific training on the guidelines being supervised in their clinical practice. As a result, trained pediatricians showed a significantly higher compliance with the international guidelines and infants with unexplained crying and distressed behaviour or with uncomplicated recurrent regurgitation and vomiting who were unproperly prescribed PPIs decreased dramatically [7]. Besides these data on PPI overuse, recent studies highlighted the occurrence of several adverse effects related to their assumption, such as a higher risk of bronchoalveolar lavage culture positivity and gastric bacterial overgrowth, food allergy, Clostridium difficile infection, gastric polyps and nodules [812].

Figure 1
figure1

Rates of pediatricians over-prescribing PPIs in the different European countries

References

  1. 1.

    Putnam PE: Stop the PPI Express: They Don't Keep Babies Quiet!. J Pediatr. 2009, 154 (4): 475-476. 10.1016/j.jpeds.2008.09.054.

    PubMed  Article  Google Scholar 

  2. 2.

    Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M: Multicenter, double-blind, randomized, placebo-controlled trial assessing efficacy & safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009, 154 (4): 514-520.e4. 10.1016/j.jpeds.2008.09.054.

    PubMed  CAS  Article  Google Scholar 

  3. 3.

    Gieruszczak-Białek D, Konarska Z, Skórka A, Vandenplas Y, Szajewska H: No effect of proton pump inhibitors on crying and irritability in infants: systematic review of randomized controlled trials. J Pediatr. 2015, 166 (3): 767-70. 10.1016/j.jpeds.2014.11.030.

    PubMed  Article  Google Scholar 

  4. 4.

    Orenstein SR: Infant GERD: symptoms, reflux episodes & reflux disease, acid & non-acid refllux--implications for treatment with PPIs. Curr Gastroenterol Rep. 2013, 15 (11): 353-

    PubMed  Article  Google Scholar 

  5. 5.

    Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, et al: Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009, 49 (4): 498-554. 10.1097/01.mpg.0000361306.15727.54.

    PubMed  Article  Google Scholar 

  6. 6.

    Quitadamo P, Papadopoulou A, Wenzl T, Urbonas V, Kneepkens F, Roman E, et al: European Pediatricians’ Approach to Children with Gastroesophageal Reflux Symptoms: Survey on the Implementation of 2009 NASPGHAN-ESPGHAN Guidelines. J Pediatr Gastroenterol Nutr. 2014, 58 (4): 505-509. 10.1097/MPG.0b013e3182a69912.

    PubMed  Article  Google Scholar 

  7. 7.

    Quitadamo P, Urbonas V, Papadopoulou A, Roman E, Pavkov DJ, Orel R, et al: Do pediatricians apply the 2009 NASPGHAN-ESPGHAN guidelines for the diagnosis and management of gastroesophageal reflux after being trained?. J Pediatr Gastroenterol Nutr. 2014, 59 (3): 356-359. 10.1097/MPG.0000000000000408.

    PubMed  Article  Google Scholar 

  8. 8.

    Rosen R, Johnston N, Hart K, Khatwa U, Katz E, Nurko S: Higher rate of bronchoalveolar lavage culture positivity in children with nonacid reflux and respiratory disorders. J Pediatr. 2011, 159 (3): 504-506. 10.1016/j.jpeds.2011.05.021.

    PubMed  PubMed Central  Article  Google Scholar 

  9. 9.

    Rosen R, Amirault J, Liu H, Mitchell P, Hu L, Khatwa U, et al: Changes in gastric and lung microflora with acid suppression: acid suppression and bacterial growth. JAMA Pediatr. 2014, 168 (10): 932-937. 10.1001/jamapediatrics.2014.696.

    PubMed  Article  Google Scholar 

  10. 10.

    Trikha A, Baillargeon JG, Kuo YF, Tan A, Pierson K, Sharma G, et al: Development of food allergies in patients with gastroesophageal reflux disease treated with gastric acid suppressive medications. Pediatr Allergy Immunol. 2013, 24 (6): 582-588. 10.1111/pai.12103.

    PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Turco R, Martinelli M, Miele E, Roscetto E, Del Pezzo M, Greco L, et al: Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther. 2010, 31 (7): 754-759.

    PubMed  CAS  Article  Google Scholar 

  12. 12.

    Pashankar DS, Israel DM: Gastric polyps and nodules in children receiving long-term omeprazole therapy. J Pediatr Gastroenterol Nutr. 2002, 35 (5): 658-662. 10.1097/00005176-200211000-00013.

    PubMed  CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Annamaria Staiano.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Staiano, A., Quitadamo, P. Use and overuse of proton pump inhibitors. Ital J Pediatr 41, A68 (2015). https://doi.org/10.1186/1824-7288-41-S2-A68

Download citation

Keywords

  • Proton Pump Inhibitor
  • Food Allergy
  • Lower Esophageal Sphincter
  • Lansoprazole
  • Gastroesophageal Reflux Disease